TY - JOUR
T1 - Ventricular Assist Device Support as a Bridge to Transplantation in Pediatric Patients
AU - Pediatric Heart Transplant Study Investigators
AU - Dipchand, Anne I.
AU - Kirk, Richard
AU - Naftel, David C.
AU - Pruitt, Elizabeth
AU - Blume, Elizabeth D.
AU - Morrow, Robert
AU - Rosenthal, David
AU - Auerbach, Scott
AU - Richmond, Marc E.
AU - Kirklin, James K.
N1 - Publisher Copyright:
© 2018 American College of Cardiology Foundation
PY - 2018/7/24
Y1 - 2018/7/24
N2 - Background: Pediatric ventricular assist device (VAD) use has evolved dramatically over the last 2 decades. Objectives: This study sought to describe the evolution of VAD support to heart transplantation (HTx) in children in a large international multicenter cohort. Methods: Using data from the Pediatric Heart Transplant Study, comparisons were made between children (<18 years) supported to HTx (January 1, 1993 to December 31, 2015) with VAD or extracorporeal membrane oxygenation (ECMO) to VAD support. Results: Of 7,135 listed patients, 5,145 underwent HTx; 995 (19.3%) were supported by a VAD (113 with congenital heart disease [CHD]). Patients with a VAD as their first device (n = 821) were older, larger, and more likely to have cardiomyopathy (80%) than patients transitioned from ECMO to VAD (n = 164). In the VAD-only cohort, 79% underwent HTx and 14% died, compared with 69% and 24% in the ECMO-to-VAD cohort, respectively. Patients with cardiomyopathy achieved HTx 84% of the time, with a 9% waitlist mortality rate compared with 55% and 36%, respectively, for CHD. Among VAD-treated patients, 79% were age >10 years in the earliest era, a percentage decreasing to 34% more recently, though neonates still represent <1%. Overall, survival at 2 and 20 years showed no difference between VAD and no support (2 years: 75% vs. 80%; 20 years: 55% vs. 54%). Post-HTx outcomes were better for durable versus temporary VADs (p < 0.01) and for continuous versus pulsatile VADs (p < 0.01) from 2005 onward; timing of VAD had no impact on post-HTx survival (p = 0.65). Conclusions: For one-quarter of a century, major advances have occurred in mechanical support technology for children, thereby expanding the capability to bridge to HTx without compromising post-HTx outcomes. Significant challenges remain, especially for neonates and patients with CHD, but ongoing innovation portends improved methods of support during the next decade.
AB - Background: Pediatric ventricular assist device (VAD) use has evolved dramatically over the last 2 decades. Objectives: This study sought to describe the evolution of VAD support to heart transplantation (HTx) in children in a large international multicenter cohort. Methods: Using data from the Pediatric Heart Transplant Study, comparisons were made between children (<18 years) supported to HTx (January 1, 1993 to December 31, 2015) with VAD or extracorporeal membrane oxygenation (ECMO) to VAD support. Results: Of 7,135 listed patients, 5,145 underwent HTx; 995 (19.3%) were supported by a VAD (113 with congenital heart disease [CHD]). Patients with a VAD as their first device (n = 821) were older, larger, and more likely to have cardiomyopathy (80%) than patients transitioned from ECMO to VAD (n = 164). In the VAD-only cohort, 79% underwent HTx and 14% died, compared with 69% and 24% in the ECMO-to-VAD cohort, respectively. Patients with cardiomyopathy achieved HTx 84% of the time, with a 9% waitlist mortality rate compared with 55% and 36%, respectively, for CHD. Among VAD-treated patients, 79% were age >10 years in the earliest era, a percentage decreasing to 34% more recently, though neonates still represent <1%. Overall, survival at 2 and 20 years showed no difference between VAD and no support (2 years: 75% vs. 80%; 20 years: 55% vs. 54%). Post-HTx outcomes were better for durable versus temporary VADs (p < 0.01) and for continuous versus pulsatile VADs (p < 0.01) from 2005 onward; timing of VAD had no impact on post-HTx survival (p = 0.65). Conclusions: For one-quarter of a century, major advances have occurred in mechanical support technology for children, thereby expanding the capability to bridge to HTx without compromising post-HTx outcomes. Significant challenges remain, especially for neonates and patients with CHD, but ongoing innovation portends improved methods of support during the next decade.
KW - durable
KW - extracorporeal membrane oxygenation
KW - heart failure
KW - outcomes
KW - survival
UR - http://www.scopus.com/inward/record.url?scp=85049738063&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85049738063&partnerID=8YFLogxK
U2 - 10.1016/j.jacc.2018.04.072
DO - 10.1016/j.jacc.2018.04.072
M3 - Article
C2 - 30025576
AN - SCOPUS:85049738063
SN - 0735-1097
VL - 72
SP - 402
EP - 415
JO - Journal of the American College of Cardiology
JF - Journal of the American College of Cardiology
IS - 4
ER -